Morning Business Report: Mounjaro study shows lower heart risk as Wall Street closes out month of gains
4 Articles
4 Articles
The FDA (Food and Drug Administration), a drug regulator in the United States, released the use of Mounjaro, pharmacist Eli Lilly, to reduce the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes and high cardiovascular risk. This expands the use of the drug based on tirzepatide, previously aimed only at controlling diabetes and subsequently used in the treatment of obesity. Nephrotic syndrome: understand what is the d…
Morning Business Report: Mounjaro study shows lower heart risk as Wall Street closes out month of gains
(LILAMAX)- A study examining the GLP-1 medication Mounjaro found it could help lower the risk of serious heart-related health problems. The study showed people who took Mounjaro had an 8% lower rate of cardiovascular death, heart attack or stroke. Meanwhile, Wall Street is preparing to wrap up a month of gains, led by the technology sector. Artificial intelligence-related stocks were...
In Brazil, indication of the drug is restricted to type two diabetes treatment and weight control
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
